Real‐World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in <scp>FAERS</scp>

XingYu Liu, WenFang Wang

Open source

DOI
10.1111/dom.71373
Published
2026-09-21
Container
Diabetes, Obesity and Metabolism
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/dom.71373,
  title = {Real‐World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in
                    <scp>FAERS</scp>},
  author = {XingYu Liu and WenFang Wang},
  year = {2026},
  journal = {Diabetes, Obesity and Metabolism},
  doi = {10.1111/dom.71373},
  url = {https://doi.org/10.1111/dom.71373}
}

RIS

TY  - JOUR
TI  - Real‐World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in
                    <scp>FAERS</scp>
AU  - XingYu Liu
AU  - WenFang Wang
PY  - 2026
JO  - Diabetes, Obesity and Metabolism
DO  - 10.1111/dom.71373
UR  - https://doi.org/10.1111/dom.71373
ER  - 

APA

Liu, X., & Wang, W. (2026). Real‐World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in <scp>FAERS</scp>. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71373

Source records